BioPharm Business News and Perspectives

Monday, July 06, 2009 IOM's Puts Arthritis Biologics Near Top of List for Comparative Studies
The Institute of Medicine puts biologic anti-inflammatory drugs near the top of its recommended list for comparative effectiveness studies...

Thursday, June 18, 2009 Biogen Gets Joint Control of Genentech Post-Rituxan Development
Genentech must stop three drug development projects but can continue lupus and RA ocrelizumab studies....

Monday, June 15, 2009 Waxman Wants to Let FDA OK Biosimilars Without Legal Authority
Rep. Henry Waxman asks White House to let FDA approve generic biologics...

Friday, June 05, 2009 FDA OKs 2-Year Reclast for Osteoporosis
Reclast (zoledronic acid) injection has been approved as the first therapy to prevent osteoporosis for 2 years with a single dose...

Friday, May 29, 2009 NIH Pops $24M into Orphan Diseases Research
NIH will put $24 million into a new program for developing drugs for rare and neglected diseases...

Thursday, May 28, 2009 Supreme Court to Hear Vioxx Case
The US Supreme Court will decide whether Merck should be protected from Vioxx shareholder suits...

Friday, May 22, 2009 Johnson & Johnson Wants Remicade Back
J&J is going to court to end its Remicade partnership with Schering-Plough due to a merger with Merck...

Friday, May 15, 2009 FDA Going Back for Second Look At Menaflex
The US FDA, responding to criticism about the Menaflex approval process, is planning to take another look...

Thursday, May 14, 2009 Taligen Nabs $26M for Inflammatory Disease Research
Taligen is focusing on developing anti-inflammatory drugs that affect the alternative complement pathway, which helps initiate inflammation...

Thursday, May 14, 2009 FDA OKs UCB's Cimzia for Moderate to Severe RA
Cimzia^® (certolizumab pegol), the only pegylated anti-TNF, has been approved for use in the US...